U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma

British Journal of Dermatology

Volumn 168, Issue 1, 2013, Pages 192-200

  Scarisbrick, Julia J ^a   Morris, S ^b   Azurdia, R ^c   Illidge, T ^d   Parry, E ^d   Graham Brown, R ^e   Cowan, R ^d   Gallop Evans, E ^f   Wachsmuth, R ^g   Eagle, M ^b   Wierzbicki, A S ^b   Soran, H ^h   Whittaker, S ^b   Wain, E M ^b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e LEICESTER ROYAL INFIRMARY   (United Kingdom)

^f VELINDRE CANCER CENTRE   (United Kingdom)

^g MUSGROVE PARK HOSPITAL   (United Kingdom)

^h MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CREATINE KINASE; GLUCOSE;

ARTICLE; BLOOD CELL COUNT; COCHRANE LIBRARY; CUTANEOUS T CELL LYMPHOMA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MONITORING; DYSLIPIDEMIA; EMBASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MEDLINE; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; THYROID DISEASE; THYROID FUNCTION; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

ADULT; AMYLASES; ANTICARCINOGENIC AGENTS; BLOOD CELL COUNT; BLOOD GLUCOSE; CHOLESTEROL, HDL; CLINICAL PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FENOFIBRATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; LIVER FUNCTION TESTS; LYMPHOMA, T-CELL, CUTANEOUS; MUSCULOSKELETAL PAIN; PANCREATITIS; PREGNANCY; PREGNANCY COMPLICATIONS; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES; THYROTROPIN; THYROXINE;

EID: 84872873340     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12042     Document Type: Article

References (41)

1. Anon. Targretin® (bexarotene). Prescribing information, 2011. Available from: http://www.drugs.com/pro/targretin.html (last accessed 5 September 2012).
2. Nieto-Rementeria N, Perez-Yarza G, Boyano MD, et al. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol 2009; 160: 519-26.
3. Food and Drug Administration. Targretin® (bexarotene) capsules, 75 mg, 2011. Available at: www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 021055s006lbl.pdf (last accessed 5 September 2012).
4. Whittaker SJ, Marsden JR, Spittle M, et al. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003; 149: 1095-107.
5. Kannangara AP, Levitan D, Fleischer AB Jr,. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma. J Dermatolog Treat 2009; 20: 169-76.
6. Straus DJ, Duvic M, Kuzel T, et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer 2007; 109: 1799-803.
7. Abbott RA, Whittaker SJ, Morris SL, et al. Bexarotene therapy for mycosis fungoides and Sézary syndrome. Br J Dermatol 2009; 160: 1299-307.
8. Talpur R, Ward S, Apisarnthanarax N, et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002; 47: 672-84.
9. Gniadecki R, Assaf C, Bagot M, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 2007; 157: 433-40.
10. Assaf C, Bagot M, Dummer R, et al. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 2006; 155: 261-6.
11. Tsirigotis P, Pappa V, Papageorgiou S, et al. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome. Br J Dermatol 2007; 156: 1379-81.
12. McGinnis KS, Junkins-Hopkins JM, Crawford G, et al. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol 2004; 50: 375-9.
13. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-71.
14. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-93.
15. British Cardiac Society, British Hypertension Society, Diabetes UK, et al. JBS 2: the Joint British Societies' guidelines for prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl.V): v1-52.
16. National Institute for Health and Clinical Excellence. Lipid modification. Clinical Guideline 67. London: NICE, 2008.
17. Zhou SF,. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008; 9: 310-22.
18. Flockhart DA,. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indianapolis, IN: Indiana University. Available at: http://medicine.iupui.edu/ clinpharm/ddis/table.aspx (last accessed 5 September 2012).
19. Talpur R, Duvic M,. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene. Clin Lymphoma Myeloma 2006; 6: 488-92.
20. Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999; 340: 1075-9.
21. Sherman SI,. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clin Lymphoma 2003; 3: 249-52.
22. Smit JW, Stokkel MP, Pereira AM, et al. Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. J Clin Endocrinol Metab 2007; 92: 2496-9.
23. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). JAMA 2001; 285: 2486-97.
24. Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 2003; 19: 155-68.
25. Jones PH, Davidson MH,. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95: 120-2.
26. Davidson MH, Maki KC, Kalkowski J, et al. Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial. J Am Coll Nutr 1997; 16: 236-43.
27. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels [from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension (MARINE) trial]. Am J Cardiol 2011; 108: 682-90.
28. Musolino A, Panebianco M, Zendri E, et al. Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids. Br J Haematol 2009; 145: 84-6.
29. Wierzbicki AS,. Niacin: the only vitamin that reduces cardiovascular events. Int J Clin Pract 2011; 65: 379-85.
30. Lloret-Linares C, Pelletier AL, Czernichow S, et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas 2008; 37: 13-22.
31. Farnier M, Roth E, Gil-Extremera B, et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J 2007; 153: 335-8.
32. Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005; 21: 959-69.
33. Farnier M, Freeman MW, MacDonell G, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005; 26: 897-905.
34. Sacks FM,. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002; 90: 139-43.
35. McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 97: 89C-94C.
36. Mukherjee R, Davies PJ, Crombie DL, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386: 407-10.
37. de Vries-van der Weij J, de Haan W, Hu L, et al. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. Endocrinology 2009; 150: 2368-75.
38. Keating GM, Croom KF,. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007; 67: 121-53.
39. Carswell CI, Plosker GL, Jarvis B,. Rosuvastatin. Drugs 2002; 62: 2075-85.
40. Soran H, Durrington P,. Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opin Pharmacother 2008; 9: 2145-60.
41. Dummer R, Beyer M, Hymes K, et al. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leuk Lymphoma 2012; 53: 1501-8.